blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3294285

EP3294285 - CABAZITAXEL AND ITS USE FOR TREATING CANCER [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  16.12.2022
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  15.11.2019
FormerGrant of patent is intended
Status updated on  09.07.2019
FormerRequest for examination was made
Status updated on  16.02.2018
FormerThe international publication has been made
Status updated on  18.11.2016
Most recent event   Tooltip16.12.2022Revocation of patentpublished on 18.01.2023  [2023/03]
Applicant(s)For all designated states
Sanofi Mature IP
54 rue la Boétie
75008 Paris / FR
[2019/40]
Former [2018/12]For all designated states
Aventis Pharma S.A.
20, avenue Raymond Aron
92160 Antony / FR
Inventor(s)01 / CHADJAA, Mustapha
c/o Sanofi
Patent Department
54 rue La Boétie
75008 Paris / FR
02 / DEDIEU, Jean-François
c/o Sanofi
Patent Department
54 rue La Boétie
75008 Paris / FR
03 / GUPTA, Sunil
c/o Sanofi
Patent Department
55 Corporate Drive
Mail code 55A-505A
Bridgewater, New Jersey 08807 / US
04 / SELLAMI, Dalila
1
Cedar Tree Lane
Chester NJ 07930 / US
05 / SEMIOND, Dorothée
c/o Sanofi
Patent Department
55 Corporate Drive
Mail Code 55A-505A, Bridgewater
NJ 08807 / US
 [2018/12]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2019/51]Sanofi
54, rue La Boétie
75008 Paris / FR
Former [2018/12]Quellari, Mylène Audrey Séverine, et al
Sanofi
Département Brevets
54, rue La Boétie
75008 Paris / FR
Application number, filing date16721844.512.05.2016
[2018/12]
WO2016EP60759
Priority number, dateEP2015030572013.05.2015         Original published format: EP 15305720
[2018/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016180943
Date:17.11.2016
Language:EN
[2016/46]
Type: A1 Application with search report 
No.:EP3294285
Date:21.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 17.11.2016 takes the place of the publication of the European patent application.
[2018/12]
Type: B1 Patent specification 
No.:EP3294285
Date:18.12.2019
Language:EN
[2019/51]
Search report(s)International search report - published on:EP17.11.2016
ClassificationIPC:A61K31/337, A61P35/00
[2018/12]
CPC:
A61K31/337 (EP,KR,US); A61J1/00 (KR,US); A61P1/16 (EP);
A61P13/08 (EP); A61P35/00 (EP,KR); A61J2205/30 (KR,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/12]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:CABAZITAXEL UND DESSEN VERWENDUNG ZUR BEHANDLUNG VON KREBS[2018/12]
English:CABAZITAXEL AND ITS USE FOR TREATING CANCER[2018/12]
French:CABAZITAXEL ET SON UTILISATION POUR LE TRAITEMENT DU CANCER[2018/12]
Entry into regional phase13.12.2017National basic fee paid 
13.12.2017Designation fee(s) paid 
13.12.2017Examination fee paid 
Examination procedure23.11.2017Date on which the examining division has become responsible
13.12.2017Examination requested  [2018/12]
25.06.2018Amendment by applicant (claims and/or description)
10.07.2019Communication of intention to grant the patent
12.11.2019Fee for grant paid
12.11.2019Fee for publishing/printing paid
12.11.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19209255.9  / EP3643307
Opposition(s)Opponent(s)01  03.06.2020  28.09.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Aera A/S, et al, et al
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 02  09.06.2020  12.10.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  01.07.2020  28.09.2020  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020  28.09.2020  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020  28.09.2020  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020  28.09.2020  ADMISSIBLE
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020  28.09.2020  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020  28.09.2020  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 [N/P]
Former [2022/18]
Opponent(s)01  03.06.2020  28.09.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Aera A/S, et al, et al
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 02  09.06.2020  12.10.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  01.07.2020  28.09.2020  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020  28.09.2020  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020  28.09.2020  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020  28.09.2020  ADMISSIBLE
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020  28.09.2020  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020  28.09.2020  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
Former [2021/52]
Opponent(s)01  03.06.2020  28.09.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020  12.10.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  01.07.2020  28.09.2020  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020  28.09.2020  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020  28.09.2020  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020  28.09.2020  ADMISSIBLE
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020  28.09.2020  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020  28.09.2020  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
Former [2021/46]
Opponent(s)01  03.06.2020  28.09.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020  12.10.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  01.07.2020  28.09.2020  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020  28.09.2020  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020  28.09.2020  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020  28.09.2020  ADMISSIBLE
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020  28.09.2020  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020  28.09.2020  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
Former [2021/20]
Opponent(s)01  03.06.2020  28.09.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020  28.09.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  01.07.2020  28.09.2020  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020  28.09.2020  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020  28.09.2020  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020  28.09.2020  ADMISSIBLE
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020  28.09.2020  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020  28.09.2020  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
Former [2021/08]
Opponent(s)01  03.06.2020  28.09.2020  ADMISSIBLE
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020  28.09.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  01.07.2020  28.09.2020  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020  28.09.2020  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020  28.09.2020  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020  28.09.2020  ADMISSIBLE
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020  28.09.2020  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020  28.09.2020  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
Former [2020/44]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020   
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Best, Michael, et al, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
 03  01.07.2020   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020   
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020   
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020   
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 08  18.09.2020  23.09.2020  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Greiner, Elisabeth, et al, et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 09  18.09.2020   
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
Former [2020/43]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020   
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Best, Michael, et al, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
 03  01.07.2020   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020   
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 06  16.09.2020   
Generics [UK] Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner, et al, et al
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 07  17.09.2020   
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
Former [2020/40]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020   
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Best, Michael, et al, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
 03  01.07.2020   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
 05  26.08.2020   
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2020/34]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020   
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
 03  01.07.2020   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  09.07.2020   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg / DE
Former [2020/33]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020   
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
 03  01.07.2020   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2020/30]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
 02  09.06.2020  16.06.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Former [2020/28]
Opponent(s)01  03.06.2020   
Accord Healthcare
Sage House, 319 Pinner Road
North Harrow Middlesex HA1 4HF / GB
Opponent's representative
Accord Healthcare, S.L.U., et al, et al
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6ª planta
08039 Barcelona / ES
31.08.2020No. 01: Notification indicating deficiencies in the notice of opposition
31.08.2020No. 02: Notification indicating deficiencies in the notice of opposition
31.08.2020No. 03: Notification indicating deficiencies in the notice of opposition
31.08.2020No. 04: Notification indicating deficiencies in the notice of opposition
31.08.2020No. 05: Notification indicating deficiencies in the notice of opposition
17.09.2020No. 01: Reply to notification indicating deficiencies in the notice of opposition
17.09.2020No. 02: Reply to notification indicating deficiencies in the notice of opposition
18.09.2020No. 03: Reply to notification indicating deficiencies in the notice of opposition
18.09.2020No. 04: Reply to notification indicating deficiencies in the notice of opposition
18.09.2020No. 05: Reply to notification indicating deficiencies in the notice of opposition
05.10.2020Invitation to proprietor to file observations on the notice of opposition
15.04.2021Reply of patent proprietor to notice(s) of opposition
07.09.2021Cancellation of oral proceeding that was planned for 16.05.2022
16.05.2022Date of oral proceedings
30.08.2022Cancellation of oral proceeding that was planned for 14.09.2022
02.09.2022Despatch of communication that the patent will be revoked
12.09.2022Legal effect of revocation of patent [2023/03]
14.09.2022Date of oral proceedings
Fees paidRenewal fee
11.05.2018Renewal fee patent year 03
15.05.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.05.2016
AL18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MK18.12.2019
MT18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
IE12.05.2020
LU12.05.2020
GB18.11.2020
[2022/32]
Former [2022/28]HU12.05.2016
AL18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MT18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
IE12.05.2020
LU12.05.2020
GB18.11.2020
Former [2021/20]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
IE12.05.2020
LU12.05.2020
GB18.11.2020
Former [2021/15]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
LU12.05.2020
GB18.11.2020
Former [2021/10]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
GB18.11.2020
Former [2020/51]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
Former [2020/47]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
Former [2020/40]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
IS18.04.2020
Former [2020/37]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/36]AL18.12.2019
CZ18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/35]AL18.12.2019
CZ18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/32]AL18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/26]HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/23]LT18.12.2019
LV18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/22]LT18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/21]NO18.03.2020
Cited inInternational search[X]  - "Jevtana (cabazitaxel) Injection, 60 mg/1.5 mL, for intravenous infusion only - Prescribing Information", INTERNET CITATION, (201210), pages 1 - 25, URL: http://products.sanofi.us/jevtana/jevtana.html, (20130514), XP002697031 [X] 1-5,9-12 * page 2, paragraph 2 * * page 11, paragraph 5.6 * * page 17, paragraph 8.7 *
 [XI]  - JOERGER MARKUS, "Metabolism of the taxanes including nab-paclitaxel.", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY MAY 2015, (20141114), vol. 11, no. 5, ISSN 1744-7607, pages 691 - 702, XP009185790 [X] 1-5,9-16,18,19 * page 696, column l, paragraph 4.2 * [I] 1-5,9-20

DOI:   http://dx.doi.org/10.1517/17425255.2015.983074
 [A]  - TSAO CHE-KAI ET AL, "Metabolic and toxicological considerations of newly approved prostate cancer drugs", EXPERT OPINION DRUG METABOLISM & TOXICOLOGY, (201307), vol. 9, no. 7, pages 835 - 846, XP009185791 [A] 1-20 * page 841, column r, paragraph 3.1.8 * * page 842, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1517/17425255.2013.789019
 [A]  - HEIDENREICH A ET AL, "Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 63, no. 6, doi:10.1016/J.EURURO.2012.08.058, ISSN 0302-2838, (20130601), pages 977 - 982, (20120903), XP002697032 [A] 1-20 * page 981, column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.eururo.2012.08.058
 [A]  - YOON-KOO KANG ET AL, "A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)", CANCER CHEMOTHERAPY AND PHARMACOLOGY, (20141209), vol. 75, no. 2, doi:10.1007/s00280-014-2638-y, ISSN 0344-5704, pages 309 - 318, XP055176633 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00280-014-2638-y
by applicantWO9630355
 US5847170
 EP0817779
 WO2005028462
    - J. PHARM. SCI., (1975), vol. 64, no. 8, pages 1269 - 1288
OppositionWO2011051894
 WO2016180943
    - Anonymous, "CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) APPLICA TION NUMBER: 201023", CENTER FOR DRUG EVALUATION AND RESEARCH, (20100331), pages 1-44, 51 - 76, XP055770059
    - V. Dieras, A. Lortholary, V. Laurence , R. Delva, V. Girre, A. Livartowski, S. Assadourian, D. Semiond, J.Y. Pierga, "Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study", European Journal of Cancer, (20120910), vol. 49, pages 25 - 34, XP055770114
    - M. Joerger, J. H. Beumer, "Cancer treatment in patients with Hepatic Dysfunction", M. Joerger, J. H. Beumer, Veronika Ballova , Mariano Provencio Pulla, ESMO HANDBOOK OF CANCER TREATMENTS IN SPECIAL CLINICAL SITUATIONS, ESMO Press, (20130000), pages 4pp, v-xii, 22 - 29, XP055770126
    - U.S. National Library of Medicine, "Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment", ClinicalTrials.gov archive, Study NCT01140607, (20140819), pages 1 - 9, XP055770132
    - Daniel P. Petrylak, "Practical guide to the use of chemotherapy in castration resistant prostate cancer", The Canadian Journal of Urology, (20140400), vol. 21, no. Suppl 1, pages 77 - 83, XP055770135
    - "Microtubule-Targeting Drugs", Alfred E. Chang, Patricia A. Ganz, Daniel F. Hayes, Timothy J. Kinsella, Harvey I. Pass, Joan H. Schiller, Richard M. Stone, Victor J. Strecker, Oncology An Evidence-Based Approach, Springer Science+Business Media, Inc., (20060000), pages 2pp, 33 - 35, XP055770139
    - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - JEVTANA (cabazitaxel)", (20100600), pages 1 - 25, XP055770144
    - Anonymous, "Assessment Report For Jevtana (cabazitaxel) Procedure No.: EMEA/H/C/002018", European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP), (20110120), pages 1 - 66, XP055511201
    - Anonymous, "Australian Public Assessment Report for Cabazitaxel", Therapeutic Goods Administration (TGA), (20120209), pages 1 - 61, XP055770157
    - Anonymous, "Phase 1 Safety and Pharmacokinetic Study ofXRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment", Sanofi, (20150716), pages 1 - 5, XP055770165
    - Anonymous, "Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment", ClinicalTrials.gov archive, Study NCT01140607, (20130000), pages 1 - 11, XP055770172
    - Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, Frangois Kleinclauss, Xavier Pivot and Antoine Thiery-Vuillemin, "Safety and efficacy of cabazitaxel in the docetaxel- treated patients with hormone-refractory prostate cancer", Clinical Medicine Insights: Oncology, (20121220), vol. 7, pages 1 - 12, XP055770176
    - Anonymous, "Mosteller-Formel, Wikipedia", (20190530), pages 1 - 2, URL: https://de.wikipedia.org/w/index.php?title=Mosteller-Formel&oldid=189073314, XP055770179
    - Anonymous, "History of Study NCT01140607. Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment", clinicaltrials.gov Study NCT01140607, (20140819), URL: https://clinicaltrials.gov/ct2/history/NCT01140607?V_35=View#StudyPageTop, XP055771195
    - MITA et al., "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clin Cancer Res, (20090115), vol. 15, no. 2, page 723, XP002623316

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
    - Joerger Markus, "Metabolism of the taxanes including nab-paclitaxel, Expert Opinion on Drug Metabolism & Toxicology", Expert opinion on drug metabolism & toxicology, (20150501), vol. 11, no. 5, pages 691 - 702, XP009185790

DOI:   http://dx.doi.org/10.1517/17425255.2015.983074
    - HOOKER et al., "Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements", Clin Pharmacol Ther, (20080700), vol. 84, no. 1, pages 111 - 118, XP055770850

DOI:   http://dx.doi.org/10.1038/sj.clpt.6100476
    - "3 Cancer Treatment In Patients with Hepatic Dysfunction", M. JORGER et al, ESMO Handbook of Cancer Treatment in special clinical situations, ESMO Press, (20130000), pages 22 - 29, XP055771210
    - FDA, "Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling", FDA Guidance for Industry, (20030500), XP055771219
    - FDA, "Jevtana 60 mg concentrate and solvent for solution for infusion", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20110322), pages 1 - 34, XP055771233
    - Afroz Abidi, "Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-currentimplications and future prospects", J. Pharmacol. Pharmacother., (20131000), vol. 4, no. 4, pages 230 - 237, XP055771588
    - "Assessment Report For Jevtana (cabazitaxel) Procedure No.: EMEA/H/C/002018 UPA", EMA Assessment Report, (20110100), XP055511201
    - Eric Raymond et al, "Dosage Adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction", Journal of Clinical Oncology, (20020000), vol. 20, no. 21, pages 4303 - 4312, XP055771602
    - "Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling", Guidance for Industry, (20030500), XP055771219
    - A P Venook et al, "Phase I and Pharmacokinetic Trial of Paclitaxel in Patients With Hepatic Dysfunction: Cancer and Leukemia Group B 9264", Abstract of Journal of Clinical Oncology, (19980000), vol. 16, no. 5, pages 1811 - 1819, XP055771614
    - Hironobu Minami et al, "Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice", Cancer Sci, (20090000), vol. 100, no. 1, pages 144 - 149, XP055771619
    - Alain C. Mita et al, "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clin Cancer Res, (20090000), vol. 15, no. 2, pages 723 - 730, XP002623316

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
    - GALSKY et al., "Cabazitaxel", Nature Reviews, Drug Discovery, (20100000), vol. 9, doi:10.1038/nrd3254, XP002623319

DOI:   http://dx.doi.org/10.1038/nrd3254
    - SARTOR et al., "Improving Outcomes with Recent Advances in Chemotherapy for Castrate-Resistant Protaste Cancer", Clinical Genitourinary Cancer, (20100000), vol. 8, doi:10.3816/CGC.2010.n.004, XP009149078

DOI:   http://dx.doi.org/10.3816/CGC.2010.n.004
    - "JEVTANA (cabazitaxel) Injection", HIGHLIGHTS OF PRESCRIBING INFORMATION, (201006), pages 1 - 25, XP055770144
    - "JEVTANA (cabazitaxel) injection", HIGHLIGHTS OF PRESCRIBING INFORMATION, (201801), pages 1 - 28, XP055772501
    - CENTER FOR DRUG EVALUATION AND RESEARCH,, "CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)", (20100331), XP055770059
    - "Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment", ClinicalTrials.gov archive, Study NCT01140607, (20100608), XP055770132
    - DIERAS et al., "Cabzitaxel in patients with advanced solid tumors: Results of a Phase I and pharmacokinetic study", European Journal of Cancer, (20130000), vol. 49, pages 25 - 34, XP055770114
    - Field and Michael, "Part II: Liver function in oncology: towards safer chemotherapy use", Lancet Oncol, (20081200), vol. 9, pages 1181 - 1190, XP025695502

DOI:   http://dx.doi.org/10.1016/S1470-2045(08)70307-3
    - VENOOK et al., "Phase I and Pharmacokinetic Trial of Paclitaxel in Patients with Hepatic Dysfunction: Cancer and Leukemia Group B 9264", Journal of Clinical Oncology, (19980500), vol. 16, no. 5, pages 1811 - 1819, XP055771666

DOI:   http://dx.doi.org/10.1200/JCO.1998.16.5.1811
    - EMA, "Assessment Report For Jevtana (cabazitaxel) Procedure No.: EMEA/H/C/002018", (20110120), XP055511201
    - "Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment", ClinicalTrials.gov archive, Study NCT01140607, (20140819), XP055770132
    - KANG, Y.K. et al., "A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)", Cancer Chemother. Pharmacol., (20150000), vol. 75, pages 309 - 318, XP035434974

DOI:   http://dx.doi.org/10.1007/s00280-014-2638-y
    - "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling", FDA Guidance for Industry, (20030500), XP055771219
    - ABRAMS, J. et al., "A Handbook for Clinical Investigators Conducting Therapeutic Clinical Trials Supported by CTEP, DCTD, NCI", Investigator's Handbook, Version 1.2, (20140000), pages 13 - 19, XP055772536
    - "Specific Instructions for the Use of Protocol Templates for Organ Dysfunction Studies", CTEP Organ Dysfunction Working Group Protocol Template, (20141126), XP055772544
    - FERRON, G.M. et al., "Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors", Cancer Chemother. Pharmacol., (20130000), vol. 71, pages 681 - 692, XP035339913

DOI:   http://dx.doi.org/10.1007/s00280-012-2058-9
    - ECKMANN, K. et al., "Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases", J. Oncol. Pharm. Practice, (20140000), vol. 20, no. 2, pages 120 - 129, XP055817881

DOI:   http://dx.doi.org/10.1177/1078155213480536
    - GIBALDI, M. et al., BIOPHARMACEUTICS AND CLINICAL PHARMACOKINETICS, 2nd ed., (19770000), page 123, XP055817897
    - "JEVTANA (cabazitaxel) Injection", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20100600), pages 1 - 25, XP055770144
    - "CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) APPLICATION NUMBER: 201023", (20100331), XP055770059
    - Australian Public Assessment Report (AusPAR) for Cabazitaxel, (20120200), XP055770157
    - TSAO et al., "Clinical Development of cabazitaxel for the Treatment of Castration- Resistant Prostate Cancer", Clinical Medicine Insights: Oncology, (20110000), vol. 5, pages 163 - 169, XP055772558

DOI:   http://dx.doi.org/10.4137/CMO.S6566
    - "Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function", CHMP, (20050217), pages 1 - 10, XP055772570
    - "Pharmacokinetics in patients with impaired hepatic function: study, design, data analysis, and impact on dosing and labelling", Guidance for Industry, (20030500), XP055771219
    - Joerger et al., "Chapter 3 - Cancer treatment in patients with Hepatic Dysfunction", Joerger et al., BALLOVÁ et al., ESMO HANDBOOK OF CANCER TREATMENTS IN SPECIAL CLINICAL SITUATIONS, (20130000), pages 22 - 29, XP055770126
    - anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - JEVTANA (cabazitaxel)", (20100600), pages 1 - 25, XP055770144
    - Anonymous, "CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) APPLICA TION NUMBER: 201023", CENTER FOR DRUG EVALUATION AND RESEARCH,, (20100331), pages 1-44, 51 - 76, XP055770059
    - Fda, "Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling", FDA Guidance for Industry, (20030500), XP055771219
    - A P Venook, M J Egorin, G L Rosner, T D Brown, T M Jahan, G Batist, R Hohl, D Budman, M J Ratain, C M Kearns, R L Schilsky, "Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264", Journal of Clinical Oncology, (19980000), vol. 16, no. 5, pages 1811 - 1819, XP055771666

DOI:   http://dx.doi.org/10.1200/JCO.1998.16.5.1811
    - Field K M; Michael M, "Part II: Liver function in oncology: towards safer chemotherapy use", Lancet Oncology, (20080000), vol. 9, no. 12, doi:10.1016/S1470-2045(08)70307-3, pages 1181 - 1190, XP025695502

DOI:   http://dx.doi.org/10.1016/S1470-2045(08)70307-3
    - Sarantopoulos John; Mita Alain C; He Aiwu; Wade James L; Hsueh Chung-Tsen; Morris John C; Lockhart A Craig; Quinn David I; Hwang Jimmy; Mier James; Zhang Wenping; Wack Claudine; Yin Jian; Clot Pierre-François; Rixe Olivier, "Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study", Cancer chemotherapy and pharmacology, (20170105), vol. 79, no. 2, pages 339 - 351, XP036149300

DOI:   http://dx.doi.org/10.1007/s00280-016-3210-8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.